SEC Form 4 · accession 0001562180-16-001734
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Taylor Behrens
Director
Period of report
Feb 18, 2016
Accepted (ET)
Feb 22, 2016 · 12:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 18, 2016 | M | 930 | $0.00 | A | 5,080 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Feb 18, 2016 | M | 930 | D | — | — | Common Stock | 930 | 1,860 | D |
Explanation of responses
- F1Vesting of restricted stock units.
- F2Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
- F3The restricted stock units vest in four equal annual installments beginning on February 18, 2015. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.